Researchers from Vicero Inc. have developed a Vincobody platform, which allows for design of novel proprietary VHH antibody fragments that possess the efficacy of dual checkpoint blockade while mitigating the toxicity limitations of current monoclonal antibody therapies.

Combining the direct cytotoxic effects of antibody-drug conjugates (ADCs) with the immune-enhancing properties of immunostimulators represents a new therapeutic strategy that could not only eradicate tumor cells, but also reprogram the tumor microenvironment, leading to durable and systemic anticancer immunity. Using this new approach, researchers from Bioray Pharmaceutical Co. Ltd. developed and characterized of a new dual drug ADC (BiADC), named BR-113, designed to target human (h)Trop2.

RAS G12D is one of the most frequent mutations in RAS, and when it occurs, it leaves RAS in a permanently active state, causing the cell to proliferate uncontrollably. Examples of the so-called RAS-addicted cancers are colorectal cancer or pancreatic ductal adenocarcinoma.